{"id":952670,"date":"2026-04-19T19:48:08","date_gmt":"2026-04-19T23:48:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next-generation-single-and-dual-payload-adc-programs-at-aacr-2026\/"},"modified":"2026-04-19T19:48:08","modified_gmt":"2026-04-19T23:48:08","slug":"sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next-generation-single-and-dual-payload-adc-programs-at-aacr-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next-generation-single-and-dual-payload-adc-programs-at-aacr-2026\/","title":{"rendered":"Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026"},"content":{"rendered":"
\n

\n STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing <\/em>
\n solid tumor PDX models, with improved efficacy versus benchmark ADCs<\/em>\n <\/p>\n

\n STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models<\/em>\n <\/p>\n

\n Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro\u2019s platform for developing dual-payload ADCs<\/em>\n <\/p>\n

SOUTH SAN FRANCISCO, Calif., April 19, 2026 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced promising preclinical data across its pipeline of next- generation ADCs in five posters and one oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026. Of note, results from a preclinical study of STRO-004, its DAR8 Topo1 ADC targeting Tissue Factor (TF), were reviewed today in an oral presentation titled \u201cSTRO-004, an exatecan-based next-generation tissue factor (TF)-targeted ADC, demonstrates superior efficacy across TF-expressing solid tumors in a comprehensive single-mouse PDX trial.\u201d<\/p>\n

In the preclinical study, STRO-004 demonstrated robust and consistent antitumor activity across a broad range of TF-expressing solid tumor patient-derived xenograft (PDX) models, with improved efficacy compared to benchmark ADCs. At a single, clinically relevant dose of 5 mg\/kg, STRO-004 achieved remarkable disease control and tumor reduction across multiple tumor types. STRO-004\u2019s favorable tolerability, with a highest non-severely toxic dose (HNSTD) of 50 mg\/kg, and pharmacokinetic profile are expected to enable increased drug exposure and payload delivery, supporting the Company\u2019s belief that STRO-004 will demonstrate superior depth and durability of response in the clinic. Exploratory biomarker analyses provide preliminary insight into STRO-004’s mechanism of action, suggesting potential for combination studies addressing specific indications in either early or late lines of treatment.<\/p>\n

\u201cThe STRO-004 preclinical data presented today underscore the potential of our next-generation ADCs to drive meaningful activity across multiple solid tumors,\u201d said Jane Chung, Sutro\u2019s Chief Executive Officer. \u201cAs STRO-004 advances in the clinic \u2013 with initial results from our Phase 1 study expected in mid-2026 \u2013 these preclinical data further strengthen our confidence in its potential across indications. More broadly, they underscore the versatility of our platform to generate differentiated ADCs across many targets and payloads, supporting a pipeline designed to address significant unmet need in cancer.\u201d<\/p>\n

In addition to the oral presentation, Sutro will present multiple posters highlighting advances across its ADC pipeline and discovery platforms, the full details of which are included below.<\/p>\n

\n Select Poster Highlights:<\/strong>\n <\/p>\n